
Ami Fadia
Stock Analyst at Needham
(4.97)
# 88
Out of 5,136 analysts
631
Total ratings
56.8%
Success rate
31%
Average return
Main Sectors:
Stocks Rated by Ami Fadia
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| JAZZ Jazz Pharmaceuticals | Maintained: Buy | $310 → $308 | $241.55 | +27.51% | 75 | Nov 16, 2026 | |
| DFTX Definium Therapeutics | Reiterated: Buy | $66 | $32.08 | +105.74% | 13 | Nov 10, 2026 | |
| BIIB Biogen | Reiterated: Buy | $256 → $290 | $253.40 | +14.44% | 73 | Oct 29, 2026 | |
| ACAD Acadia Pharmaceuticals | Reiterated: Buy | $35 | $18.75 | +86.67% | 41 | Oct 19, 2026 | |
| ALKS Alkermes | Reiterated: Buy | $62 | $47.03 | +31.83% | 20 | Oct 19, 2026 | |
| HRMY Harmony Biosciences Holdings | Reiterated: Buy | $50 | $33.76 | +48.10% | 55 | Oct 19, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $204 | $167.40 | +21.86% | 45 | Oct 16, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $268 | $141.69 | +89.15% | 27 | Oct 15, 2026 | |
| RVMD Revolution Medicines | Reiterated: Buy | $275 | $172.29 | +59.61% | 37 | Oct 15, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $68 | $43.01 | +58.10% | 1 | Oct 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $582 | $328.13 | +77.37% | 27 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $45 → $43 | $7.25 | +493.10% | 9 | Aug 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.4289 | +1,065.77% | 21 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $28.56 | - | 28 | Aug 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $32 → $39 | $19.10 | +104.19% | 6 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $11 → $18 | $3.71 | +385.18% | 32 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 → $14 | $3.37 | +315.43% | 44 | Jul 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €108.00 | €67.25 | n/a | 8 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $9.19 | n/a | 1 | Dec 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $7 | $16.66 | n/a | 2 | Mar 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 → $15 | $3.09 | n/a | 3 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $20.82 | n/a | 6 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $63 | $16.24 | n/a | 10 | Mar 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $5.5 → $6 | $21.38 | n/a | 9 | Feb 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 | $11.38 | n/a | 9 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $75 | $36.46 | n/a | 7 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5 | $0.000001 | n/a | 5 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19 → $24 | $0.3105 | n/a | 9 | Dec 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $1.5 | $0.000001 | n/a | 4 | Oct 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 → $9 | $13.65 | n/a | 4 | Aug 14, 2020 |
Jazz Pharmaceuticals
Nov 16, 2026
Maintained: Buy
Price Target: $310 → $308
Current: $241.55
Upside: +27.51%
Definium Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $66
Current: $32.08
Upside: +105.74%
Biogen
Oct 29, 2026
Reiterated: Buy
Price Target: $256 → $290
Current: $253.40
Upside: +14.44%
Acadia Pharmaceuticals
Oct 19, 2026
Reiterated: Buy
Price Target: $35
Current: $18.75
Upside: +86.67%
Alkermes
Oct 19, 2026
Reiterated: Buy
Price Target: $62
Current: $47.03
Upside: +31.83%
Harmony Biosciences Holdings
Oct 19, 2026
Reiterated: Buy
Price Target: $50
Current: $33.76
Upside: +48.10%
Neurocrine Biosciences
Oct 16, 2026
Reiterated: Buy
Price Target: $204
Current: $167.40
Upside: +21.86%
Axsome Therapeutics
Oct 15, 2026
Reiterated: Buy
Price Target: $268
Current: $141.69
Upside: +89.15%
Revolution Medicines
Oct 15, 2026
Reiterated: Buy
Price Target: $275
Current: $172.29
Upside: +59.61%
LB Pharmaceuticals
Oct 2, 2026
Initiated Coverage: Buy
Price Target: $68
Current: $43.01
Upside: +58.10%
Sep 24, 2026
Reiterated: Buy
Price Target: $582
Current: $328.13
Upside: +77.37%
Aug 31, 2026
Rated: Buy
Price Target: $45 → $43
Current: $7.25
Upside: +493.10%
Aug 14, 2026
Reiterated: Buy
Price Target: $5
Current: $0.4289
Upside: +1,065.77%
Aug 11, 2026
Rated: Hold
Price Target: n/a
Current: $28.56
Upside: -
Aug 6, 2026
Reiterated: Buy
Price Target: $32 → $39
Current: $19.10
Upside: +104.19%
Aug 5, 2026
Reiterated: Buy
Price Target: $11 → $18
Current: $3.71
Upside: +385.18%
Jul 30, 2026
Reiterated: Buy
Price Target: $15 → $14
Current: $3.37
Upside: +315.43%
Apr 25, 2025
Reiterated: Buy
Price Target: €108.00
Current: €67.25
Upside: n/a
Dec 14, 2022
Initiated Coverage: Hold
Price Target: n/a
Current: $9.19
Upside: n/a
Mar 10, 2021
Reiterated: Buy
Price Target: $10 → $7
Current: $16.66
Upside: n/a
Mar 8, 2021
Reiterated: Buy
Price Target: $10 → $15
Current: $3.09
Upside: n/a
Mar 2, 2021
Rated: Hold
Price Target: n/a
Current: $20.82
Upside: n/a
Mar 1, 2021
Rated: Buy
Price Target: $63
Current: $16.24
Upside: n/a
Feb 26, 2021
Rated: Hold
Price Target: $5.5 → $6
Current: $21.38
Upside: n/a
Feb 25, 2021
Rated: Buy
Price Target: $16
Current: $11.38
Upside: n/a
Feb 25, 2021
Rated: Hold
Price Target: $75
Current: $36.46
Upside: n/a
Jan 11, 2021
Reiterated: Buy
Price Target: $5
Current: $0.000001
Upside: n/a
Dec 2, 2020
Reiterated: Buy
Price Target: $19 → $24
Current: $0.3105
Upside: n/a
Oct 1, 2020
Reiterated: Hold
Price Target: $1 → $1.5
Current: $0.000001
Upside: n/a
Aug 14, 2020
Reiterated: Buy
Price Target: $8 → $9
Current: $13.65
Upside: n/a